Aktienanalyse zu Jaguar Health Inc (JAGX)JAGXJaguar Health Inc

Jaguar Health, Inc. is a commercial stage pharmaceuticals company. The Company is developing prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress, specifically associated with overactive bowel, which includes symptoms such as chronic debilitating diarrhea, urgency, bowel incontinence, and cramping pain. Its marketed drug Mytesi, (crofelemer 125 mg delayed-release tablets), is a first-in-class oral botanical drug product approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Its Canalevia-CA1, crofelemer delayed-release tablets drug, is an oral plant-based prescription product that is FDA conditionally approved to treat chemotherapy-induced diarrhea in dogs. It has an exclusive distribution agreement for the sale of Gelclair. It is developing a pipeline of prescription drug product candidates to address unmet needs in gastrointestinal health. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Jaguar Health Inc is not a good buy right now. The current price is $0.81, and the stock has experienced a staggering year-to-date decline of 97.68%. The RSI is at 31.68, indicating that the stock is oversold, but this does not guarantee a price recovery. The forward P/E ratio is extremely high at 200, suggesting that the stock is overvalued relative to its earnings potential. Additionally, the company reported a significant net income loss of $12.7 million in Q2 2026, which raises concerns about its financial health. The main risk is the ongoing high cash burn rate and declining revenues, with a 60% year-over-year decline in prescription product net revenue in Q2 2026, which could further strain operations if not addressed promptly.

1 analysts cover JAGX: 1 rate it Buy, 0 Hold and 0 Sell.